Cancer Drug Can Also Repair Nerves After Spinal Injury

[Please note that this page contains affiliate links. If you choose to purchase after clicking a link, I may receive a commission at no extra cost to you.]

The hopes of relieving patients from suffering from different diseases might find a solution with a single drug. For example, it has already shown promising signs of increasing the efficiency of brain cancer therapies. In addition, the medication AZD1390 has now shined in preclinical studies for regaining motion after spinal injury, possibly helping many people out of their wheelchairs.

AZD1390 may also be taken orally, as published in a Translational and Clinical Medicine paper. This will allow many more people to access medication daily without going to the hospital.

Although this research is very early, double-blind placebo clinical trials are needed to assess effectiveness and safety in real-world environments. Currently, half of these studies are happening in the form of cancer trials. In addition, spinal repair studies are limited to only mice, rats, and cell cultures, but these animal successes are awe-inspiring.

Repairing damaged nerves and battling cancers may not look like it has much in common with most people. But what brings them together is how the DNA double-strand breaks apart. As this name hints, this involves breaking both DNA strands of the double helix simultaneously, creating a danger of rearrangements in the genome. The way the body responds to double-strand breaks is it will try and repair them. Although in most cases, this is very beneficial and essential under some circumstances, it may do a lot more harm than good, and this is where the AZD1390 med comes in.

AstraZeneca is examining AZD1390 for its ability to block ataxia-telangiectasia mutated (ATM) – a protein triggered by double-strand breaks of DNA repair. As crucial as ATM is for cancer cell suppression, blocking its activity is being looked at to help make cancer cells more acceptable to radiotherapy.

Likewise, over-stimulation of this repair system is assumed to help prevent central nervous system (CNS) repair after a spinal injury. This is why Zubair Ahmed, a professor at the University of Birmingham and the research team believed AZD1390 might have recovery benefits for spinal damage. The research paper help to support the idea, as injured animals take AZD1390 for just four weeks to regain capabilities identical to their uninjured controls.

Professor Ahmed said, “It is a very exciting time for spinal cord injury research as several investigational meds are being identified as potential treatments for spinal cord injury patients. For example, we’re very excited about the drug AZD1390. It can be taken as an oral med and reaches the specific site of injury in high enough quantities to turn on nerve regeneration to restore its lost function. In addition, there is hope that safety studies for cancer therapies will give them a jump start to speed the path to the medicine’s clinical use for spinal injuries.

The research team also tested another med called KU-60019. But it promoted the same nerve growth inside of cell cultures to AZD1390, although KU-60019 didn’t have an effect when only taken orally, making it a massive disadvantage.

This research team published new evidence for animal nerve regeneration using a different drug, AZD1236, which AstraZeneca also created.

Alpha Brain

Dean Mathers

Editor-in-chief

Leave a Reply

Your email address will not be published.

25 Shares
Share
Tweet
Reddit25